Alendronate versus calcitriol for prevention of bone loss after cardiac transplantation.
Dejardin
Agnès
A
Devogelaer
Jean-Pierre
JP
Goffin
Eric
E
D019386:Alendronate / Q000627:therapeutic use*; D015519:Bone Density; D001862:Bone Resorption / Q000517:prevention & control*; D002117:Calcitriol / Q000627:therapeutic use*; D003404:Creatinine / Q000378:metabolism; D016572:Cyclosporine / Q000627:therapeutic use; D005260:Female; D016027:Heart Transplantation; D006801:Humans; D007165:Immunosuppression Therapy; D007166:Immunosuppressive Agents / Q000627:therapeutic use; D008297:Male; D011241:Prednisone / Q000627:therapeutic use; D051437:Renal Insufficiency; D016559:Tacrolimus / Q000627:therapeutic use
D007166:Immunosuppressive Agents; D016572:Cyclosporine; D003404:Creatinine; D002117:Calcitriol; D011241:Prednisone; D016559:Tacrolimus; D019386:Alendronate